EVITRADE Health Systems Corporation:
Budding Botanical Co.’s Big Vision Ready to Uproot Neutraceutical Industry
- Loading stock data…
From simple home remedies to exotic herbal therapies, from basic painkillers all the way to complex cancer treatments, medicines made from plants are an invaluable and irreplaceable marvel.Essential oils and other chemicals from the farm and garden have made their way into numerous high-tech therapies, including tobacco derivatives can cure Ebola, treating Alzheimer’s using daffodil bulbs, etc. As a result, plant-based medicineshave become a $70 billion global industry.
However, as wonderful and necessary as plants are, they do have one problem. They are not always to most efficient or consistent manufacturers in the world of nature. Like a human being, no two are ever alike, even of the same species. And like a human, some are better at making things than others.
For example, every individual plant produces a different amount of active ingredients medical scientists can use. Some plants make more of an ingredient, while others deliver a lesser yield. Or, some produce a higher quality harvest than others. Sometimes you get a hit, sometimes you miss. Simply put, quality control when using plants for medicinal purposes is always a problem.
Or is it?
What if there were a way eliminate the “hit or miss” and ensure each plant delivers a quality yield of medicinal active ingredients? How would that alter the world of medicine and the pharmaceutical industry?
Right now, there is a company working on that game-changing possibility. Of course, as with many innovative pharmaceutical ideas, change doesn’t start in a sterile Big Pharma laboratory. Instead in starts in the ambitious minds of entrepreneurs with a broad vision and the right strategic assets to radically move the needle and disrupt the way business is done.
What is this company? It’s called EVITRADE Health Systems Corp. (CSE:EVA or in the States OTCQB:AXHLF) and at the moment, it’s small in size, but big in ideas and potential. EVA’s market cap today is barely $10 million, reflective of course, of a start-up in its early stages. As a result, some of its connections are low profile – and as it’s on the ground floor, very few people on Bay Street or Wall Street have taken notice yet. But that could well change faster than a weed sprouts in a garden as the company’s story starts to spread.
Let’s take a closer look at how EVA has gotten to where it stands poised to become a potential disruptive market force.
In December 2017, EVA enjoyed a $2.25 million financing round that ended far more successfully than initially anticipated. Company management originally foresaw a $1 million round. However, resulting demand was so great, EVA upsized the offer, enabling early-bird investors to grab another 10 million shares.
Just 24 hours later, an eager investing public had bought 85 percent of those additional shares. This gave EVA $2.25 million to launch their ambitious plant-based medicine vision and assemble the assets needed to make that dream a reality.
EVA put those funds to good use right away. The company immediately engaged with Cantech Molecular Research, a specialty genetics lab. Cantech focuses on plant-based biotech. This includes analyzing biological samples on high-end lab equipment similar to those used in major research universities and breeding large quantities of vegetable clones. Cantech refers to these clones as “elite plants.”
EVA management quickly pointed out the importance of this first acquisition, saying, “The significance of this genetics technology is that it can be coupled along with advanced drug development software.This will provide the ability to engineer tailor-made, patentable drug combinations.”
In layman’s terms, the Cantech potential acquisition will enable EVA to use cloned plants to produce made-to-order pharmaceuticals that are of the same high quality each and every batch. As each plant grown and used is identical, they will produce the same mix of active ingredients as every other plant in terms of quality and quantity.
EVA’s ultimate goal is to create “large genetic mapping databases using the latest in next generation genetic sequencing platforms. The mapping will be done at a molecular level and will have the opportunity to identify the organisms’ general health.”
Such a database opens up a wide world of possibilities and opportunities for EVA, not just in the pharmaceutical world, but far beyond as well.
In pharmaceuticals, quality control is the top concern, withexceedingly high standards. Drug makers spend millions to ensure reliability and predictability. Every pill manufactured must contain the same exact mixture and quality of ingredients by law and regulation.
Ensuring constant sameness with chemicals is a tough enough job. Doing it with plants is much more difficult and costly. The process requires expensive equipment and complicated science. However, if you can know in advance that every single sprout used is going to be identical, satisfying the regulators gets a lot easier and cheaper (regulatory compliance makes up 25% of all pharmaceutical manufacturing costs).
Moving over to the $34 billion nutraceutical industry, EVA can make a significant impact there, as well. Quality control is a problem here, too. The effectiveness of each supplement or capsule can vary widely depending ingredient quality. EVA can certify exactly how much of each essential oil, flavonoid or enzyme a plant species makes. Once it maps the tissues and organizes the strains, nutraceutical companies can produce a more reliable product from the farm to pharmacy.
And, of course, EVA’s efforts can lead to healthier agriculture in a time of growing population and greater demand for nutritional food. Farmers looking for certain genetically modified crops to plant can use EVA’s resources to pick the best strains. Organic food companies can scientifically certify there are no unwanted genes in the corn, sugar, chocolate or coffee they produce.
With Cantech in discussions to ink a deal, EVA now looked to build upon its strong start by adding suitable complimentary income-generating assets. First up is a deal to buy health product marketer Artillery Labs in an all-stock deal. In exchange for up to five million shares, EVA and its investors not only gain revenue, but also a seat at the negotiating table beside the nutraceutical companies that already work with Artillery.
This is a good start that sets EVA up for future acquisitions. It’s important to note that not only is there cash remaining from December’s offering, but that the Artillery deal will not dent that fund as Artilleryis looking at an all or near all stock deal. So EVA still has plenty of flexibility and momentum to continue to grow and it has a management that is clearly thinking big – big in terms of ideas, big in terms of scientific process and big in terms investor potential.[/text_block]
This is a paid advertisement and all individuals should verify all claims and perform their own due diligence on EVA (and / or any other mentioned companies and / or securities), and read this disclaimer in its entirety.
B2B News Network profiles are not a solicitation or recommendation to buy, sell or hold securities. B2B News Network is a paid advertiser and is not offering securities for sale. Neither B2B News Network nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by B2B News Network its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations.
B2B News Network does not recommend that the securities profiled should be purchased, sold or held and is not liable for any investment decisions by its readers or subscribers.
Information presented by B2B News Network may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance, are not statements of historical fact and may be “forward-looking statements.” Forward-looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements may be identified through the use of words such as “expects,” “will,” “anticipates,” “estimates,” “believes,” “may,” or by statements indicating that certain actions “may,” “could,” or “might” occur.
THIS SITE IS PROVIDED BY B2B NEWS NETWORK ON AN “AS IS” AND “AS AVAILABLE” BASIS. B2B NEWS NETWORK MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, AS TO THE OPERATION OF THIS SITE OR THE INFORMATION, CONTENT, MATERIALS, OR PRODUCTS INCLUDED ON THIS SITE. YOU EXPRESSLY AGREE THAT YOUR USE OF THIS SITE IS AT YOUR SOLE RISK.
TO THE FULL EXTENT PERMISSIBLE BY APPLICABLE LAW, B2B NEWS NETWORK DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. SMALL CAP EXCLUSIVE DOES NOT WARRANT THAT THIS SITE, ITS SERVERS, OR E-MAIL SENT FROM B2B NEWS NETWORK ARE FREE OF VIRUSES OR OTHER HARMFUL COMPONENTS. B2B NEWS NETWORK, ITS MEMBERS, MANAGERS, OWNERS, AGENTS, AND EMPLOYEES WILL NOT BE LIABLE FOR ANY DAMAGES OF ANY KIND ARISING FROM THE USE OF THIS SITE, INCLUDING, BUT NOT LIMITED TO DIRECT, INDIRECT, INCIDENTAL, PUNITIVE, AND CONSEQUENTIAL DAMAGES.
CERTAIN STATE LAWS DO NOT ALLOW LIMITATIONS ON IMPLIED WARRANTIES OR THE EXCLUSION OR LIMITATION OF CERTAIN DAMAGES. IF THESE LAWS APPLY TO YOU, SOME OR ALL OF THE ABOVE DISCLAIMERS, EXCLUSIONS, OR LIMITATIONS MAY NOT APPLY TO YOU, AND YOU MIGHT HAVE ADDITIONAL RIGHTS.
The website contains links to other related World Wide Web Internet sites and resources. B2B News Network is not responsible for the availability of these outside resources, or their contents, nor does B2B News Network endorse nor is B2B News Network responsible for any of the contents, advertising, products or other materials on such sites. Under no circumstances shall B2B News Network be held responsible or liable, directly or indirectly, for any loss or damages caused or alleged to have been caused by use of or reliance on any content, goods or services available on such sites. Any concerns regarding any external link should be directed to its respective site administrator or webmaster.
B2B News Network is an individually owned and operated Canadian based corporation. We are paid advertisers, also known as stock touts or stock promoters, who disseminate favorable information (this “Article”) about publicly traded companies (the “Profiled Issuers”).
We publish the Information on our website, capitalequityreview.com and in newsletters, text message alerts, audio services, live interviews, featured “research” reports, on message boards and in email communications for specific time periods that are agreed upon between us and the Profiled Issuer and / or third party paying us. Our publication of the Information is known as a “Campaign”. This information may be sent to potential investors at different times that are minutes, hours, days or even weeks apart. Typically, the trading volume and price of a Profiled Issuer’s securities increases after the information is provided to the first group of investors. Therefore, the later an investor receives the Information, the more likely it is that he will suffer trading losses if they purchase the securities of a Profiled Issuer late in a Campaign. We are paid to advertise the Profiled Issuers, EVITRADE Health Systems Corp. B2B News Network has been hired by a third party, Nexalogy, for a period beginning on April 20th, 2018 to publicly disseminate information about (EVA) via website and email. We have been compensated $3,000. We will update any changes to our compensation. We own zero shares of (EVA).
Third Parties paying us to market the Profiled Issuer we believe intend to sell their shares they hold while we tell investors to purchase during the Campaign. EVITRADE Health Systems Corp. is a penny stock that was illiquid (little to no trading volume) prior to our Campaign, and therefore these securities are subject to wide fluctuations in trading price and volume. During the Campaign the trading volume and price of the securities of each Profile Issuer will likely increase significantly because of the media exposure. When the Campaign ends, the volume and price of the Profiled Issuer will likely decrease dramatically. As a result, investors who purchase during the Campaign and hold shares of the Profiled Issuer when the Campaign ends will probably lose most, if not all, of their investment.
The Information we publish in the Campaign is only a snapshot that provides only positive information about the Profiled Issuers. The Information consists of only positive content. We do not and will not publish any negative information about the Profiled Issuers; accordingly, investors should consider the Information to be one-sided and not balanced, complete, accurate, truthful and / or reliable. We do not verify or confirm any portion of the Information. We do not conduct any due diligence, nor do we research any aspect of the Information including the completeness, accuracy, truthfulness and / or reliability of the Information. We do not review the Profiled Issuers’ financial condition, operations, business model, management or risks involved in the Profiled Issuer’s business or an investment in a Profiled Issuer’s securities.
All information in our Campaign is publicly available information from 3rd party sources and / or the Profiled Issuers and/or the 3rd parties that hire us. We may also obtain the Information from publicly available sources such as the OTC Markets, Google, NASDAQ, NYSE, Yahoo, Bing, the Securities and Exchange Commission’s Edgar database or other available public sources.
We select the stocks we profile and / or pick as we are compensated to advertise them. If an investor relies solely on the Information in making an investment decision it is highly probable that the investor will lose most, if not all, of his or her investment. Investors should not rely on the Information to make an investment decision.
The source of our compensation varies depending upon the particular circumstances of the Campaign. In certain cases, we are compensated by the Profiled Issuers, third party shareholders, and / or other parties related to the Profiled Issuers such as officers and/or directors who will derive a financial or other benefit from an increase in the trading price and/or volume of a Profiled Issuer’s securities.
We make no warranty and / or representation about the Information, including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable and as such, your use of the Information is at your own risk. The Information is provided as is without limitation.
We are not, and do not act in the capacity of any of the following; as such, you should not construe our activities as involving any of the following: an independent adviser or consultant; a fortune teller; an investment adviser or an entity engaging in activities that would be deemed to be providing investment advice that requires registration either at the federal and / or state level; a broker-dealer or an individual acting in the capacity of a registered representative or broker; a stock picker; a securities trading expert; a securities researcher or analyst; a financial planner or one who engages in financial planning; a provider of stock recommendations; a provider of advice about buy, sell or hold recommendations as to specific securities; or an agent offering or securities for sale or soliciting their purchase.
There are numerous risks associated with each Profiled Issuer and investors should undertake a full review of each Profiled Issuer with the assistance of their financial, legal, and tax advisers prior to purchasing the securities of any Profiled Issuer.
We are not objective or independent and have multiple conflicts of interest. The Profiled Issuers and parties hiring us have conflicts of interest. Third parties that have hired us and own shares will sell these shares while we tell investors to purchase, and this selling of the Profiled Issuer’s securities will likely cause investors to suffer losses.
Our publication of the Information involves actual and material conflicts of interest including but not limited to the fact that we receive monetary compensation in exchange for publishing the (favorable) Information about the Profiled Issuers; and we do not publish any negative information, whatsoever, about the Profiled Issuers; in addition to the fact that while we do not own the Profiled Issuer’s securities, the third parties that hired us do, and intend to sell all of these securities during the Campaign while we publish favorable information that instructs investors to purchase, and this selling of the Profiled Issuer’s securities will likely cause investors to suffer losses.
We are not responsible or liable for any person’s use of the Information or any success or failure that is directly or indirectly related to such person’s use of the Information because we have specifically stated that the information is not reliable and should not be relied upon for any purpose. We are not responsible for omissions and / or errors in the Information and we are not responsible for actions taken by any person who relies upon the Information.
We urge Investors to conduct their own in-depth investigation of the Profiled Issuers with the assistance of their legal, tax and / or investment adviser(s). An investor’s review of the Information should include but not be limited to the Profiled Issuer’s financial condition, operations, management, products and / or services, trends in the industry and risks that may be material to the profiled Issuer’s business and other information he and his advisers deem material to an investment decision. An investor’s review should include, but not be limited to a review of available public sources and information received directly from the Profiled Issuers or from websites such as Google, Yahoo, Bing, OTC Markets, NASDAQ, NYSE, www.sec.gov or other available public sources.
We are providing you with this disclaimer because we are publishing advertisements about penny stocks. Because we are paid to disseminate the Information to the public about securities, we are required by the securities laws including Section 10(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 thereunder, and Section 17(b) of the Securities Act of 1933, as amended (the “Securities Act”), to specifically disclose our compensation as well as other important information, This information includes that we may hold, as well as purchase and sell, the securities of a Profiled Issuer before, during and after we publish favorable Information about the Profiled Issuer. We may urge investors to purchase the securities of a Profiled Issuer while we sell my own shares. The anti-fraud provisions of federal and state securities laws require us to inform you that we may engage in buying and selling of Profiled Issuer’s securities before, during and after the Campaigns.
Any investment in the Profiled Issuers involves a high degree of risk and uncertainty. The securities may be subject to extreme volume and price volatility, especially during the Campaigns. Favorable past performance of a Profiled Issuer does not guarantee future results. If you purchase the securities of the Profiled Issuers, you should be prepared to lose your entire investment. Some of the risks involved in purchasing securities of the Profiled Issuers include, but are not limited to the risks stated below.
We do not endorse, independently verify or assert the truthfulness, completeness, accuracy or reliability of the Information. We conduct no due diligence or investigation whatsoever of the Information or the Profiled Issuers and we do not receive any verification from the Profiled Issuer regarding the Information we disseminate.
If we publish any percentage gain of a Profiled Issuer from the previous day close in the Information, it is not and should not be construed as an indication that the future stock price or future operational results will reflect gains or otherwise prove to be advantageous to your investment.
The Information may contain statements asserting that a Profiled Issuer’s stock price has increased over a certain period of time which may reflect an arbitrary period of time, and is not predictive or of any analytical quality; as such, you should not rely upon the (favorable) Information in your analysis of the present or future potential of a Profiled Issuer or its securities.
The Information should not be interpreted in any way, shape, form or manner whatsoever as an indication of the Profiled Issuer’s future stock price or future financial performance.
You may encounter difficulties determining what, if any, portions of the Information are material or non-material, making it all the more imperative that you conduct your own independent investigation of the Profiled Issuer and its securities with the assistance of your legal, tax and financial advisor.
When 3rd parties that hire us acquire, purchase and / or sell the securities of the Profiled Issuers, it may (a) cause significant volatility in the Profiled Issuer’s securities; (b) cause temporary but unrealistic increases in volume and price of the Profiled Issuer’s securities; (c) if selling, cause the Profiled Issuer’s stock price to decline dramatically; and (d) permit themselves to make substantial profits while investors who purchase during the Campaign experience significant losses.
The securities of the Profiled Issuers are high risk, unstable, unpredictable and illiquid which may make it difficult for investors to sell their securities of the Profiled Issuers.
We may hire third party service providers and stock promoters to electronically disseminate live news regarding the Profiled Issuers, yet we have no control over the content of and do not verify the information that the Profiled Issuers and/or third party service providers publish. These third party service providers are likely compensated for providing positive information about the Issuer and may fail to disclose their compensation to you.
If a Profiled Issuer is a SEC reporting company, it could be delinquent (not current) in its periodic reporting obligations (i.e., in its quarterly and annual reports), or if it is an OTC Markets Pink Sheet quoted company, it may be delinquent in its Pink Sheet reporting obligations, which may result in OTC Markets posting a negative legend pertaining to the Profiled Issuer at www.otcmarkets.com, as follows: (i) “Limited Information” for companies with financial reporting problems, economic distress, or that are unwilling to file required reports with the Pink Sheets; (ii) “No Information,” which characterizes companies that are unable or unwilling to provide any disclosure to the public markets, to the SEC or the Pink Sheets; and (iii) “Caveat Emptor,” signifying buyers should be aware that there is a public interest concern associated with a company’s illegal spam campaign, questionable stock promotion, known investigation of a company’s fraudulent activity or its insiders, regulatory suspensions or disruptive corporate actions.
If the Information states that a Profiled Issuer’s securities are consistent with the future economic trends or even if your independent research indicates that, you should be aware that economic trends have their own limitations, including: (a) that economic trends or predictions may be speculative; (b) consumers, producers, investors, borrowers, lenders and/or government may react in unforeseen ways and be affected by behavioral biases that we are unable to predict; (c) human and social factors may outweigh future economic trends that we state may or will occur; (d) clear cut economic predictions have their limitations in that they do not account for the fundamental uncertainty in economic life, as well as ordinary life; (e) economic trends may be disrupted by sudden jumps, disruptions or other factors that are not accounted for in economic trends analysis; in other words, past or present data predicting future economic trends may become irrelevant in light of new circumstances and situations in which uncertainty becomes reality rather than predicted economic outcome; or (f) if the trend predicted involves a single result, it ignores other scenarios that may be crucial to make a decision in the event of unknown contingencies.
The Information is presented only as a brief snapshot of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities. You should consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.otcmarkets.com or other electronic media, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the OTCMarkets.com; (c) obtaining and reviewing publicly available information contained in commonly known search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.org. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and the OTC Markets and/or have negative legends and designations at otcmarkets.com.
FOR MORE INFORMATION AND UPDATES ON EVA, SUBSCRIBE HERE:
We value your privacy and would never spam you
Click to Invest Now